Erschienen in:
02.08.2017 | Case report
Axitinib-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic renal cell carcinoma
verfasst von:
Kogenta Nakamura, Hiroshi Saiki, Hiroyuki Muramatsu, Shingo Morinaga, Ikuo Kobayashi, Keishi Kajikawa, Genya Nishikawa, Yoshiharu Kato, Masahito Watanabe, Kent Kanao, Makoto Sumitomo
Erschienen in:
International Cancer Conference Journal
|
Ausgabe 4/2017
Einloggen, um Zugang zu erhalten
Abstract
A 61-year-old woman with metastatic renal carcinoma was treated with axitinib as a second-line tyrosine kinase inhibitor. Thirteen days after the treatment, the patient developed reversible posterior leukoencephalopathy syndrome (RPLS). Her symptoms and imaging findings resolved after withdrawal of axitinib, blood pressure control, and administration of glycerin and levetiracetam. RPLS should be kept in mind as a possible rare adverse event after axitinib administration.